A panel of experts convened by the Alzheimer’s Association and the Society of Nuclear Medicine and Molecular Imaging have issued new guidelines on the use of amyloid PET imaging in diagnosing Alzheimer's disease.
New guidelines issued for clinical use of amyloid PET imaging
Positron emission tomography (PET) of brain amyloid β is a technology that is becoming more available, but its clinical utility in medical practice requires careful definition. To provide guidance to dementia care practitioners, patients, and caregivers, the Alzheimer’s Association and the Society of Nuclear Medicine and Molecular Imaging convened the Amyloid Imaging Taskforce (AIT), which included Keith A. Johnson, MD of the Department of Radiology at Massachusetts General Hospital. The AIT considered a broad range of specific clinical scenarios in which amyloid PET could potentially be used appropriately.